The DOI matches its Crossref record; 717 of the 717 references it cites were found in a registry or an index.
ImmunoPET: Concept, Design, and Applications
Open accessAbstract
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs have been exploited to develop immunoPET probes, which has been driven by the development and optimization of radiochemistry and conjugation strategies. In addition, tumor-targeting vectors with a short circulation time (e.g., Nanobody) or with an enhanced binding affinity (e.g., bispecific antibody) are being used to design novel immunoPET probes. Accordingly, several immunoPET probes, such as 89 Zr-Df-pertuzumab and 89 Zr-atezolizumab, have been successfully translated for clinical use. By noninvasively and dynamically revealing the expression of heterogeneous tumor antigens, immunoPET imaging is gradually changing the theranostic landscape of several types of malignancies. ImmunoPET is the method of choice for imaging specific tumor markers, immune cells, immune checkpoints, and inflammatory processes. Furthermore, the integration of immunoPET imaging in antibody drug development is of substantial significance because it provides pivotal information regarding antibody targeting abilities and distribution profiles. Herein, we present the latest immunoPET imaging strategies and their preclinical and clinical applications. We also emphasize current conjugation strategies that can be leveraged to develop next-generation immunoPET probes. Lastly, we discuss practical considerations to tune the development and translation of immunoPET imaging strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 3,994
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
HaloTag: A Novel Protein Labeling Technology for Cell Imaging and Protein Analysis
Los, G. V., Encell, L. P., McDougall, M. G., Hartzell, D. D., Karassina, N., Zimprich, C., Wood, M. G., Learish, R., Ohana, R. F., Urh, M., et al. (2008) · ACS Chemical Biology · doi:10.1021/cb800025k · Cited by 2,624
Smolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., Kavanaugh, A., McInnes, I. B., Solomon, D. H., Strand, V., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.1 · Cited by 2,445
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Diagnosis and Management of Rheumatoid Arthritis: A Review
Aletaha, D., & Smolen, J. S. (2018) · JAMA · doi:10.1001/jama.2018.13103 · Cited by 2,313
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels−Alder Reactivity
Blackman, M. L., Royzen, M., & Fox, J. M. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8053805 · Cited by 1,679
(1997) · PubMed · Cited by 1,541
Image-guided cancer surgery using near-infrared fluorescence
Vahrmeijer, A. L., Hutteman, M., van der Vorst, J. R., van de Velde, C. J. H., & Frangioni, J. V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.123 · Cited by 1,466
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Ametamey, S. M., Honer, M., & Schubiger, P. A. (2008) · Chemical Reviews · doi:10.1021/cr0782426 · Cited by 1,271
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Molecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications
James, M. L., & Gambhir, S. S. (2012) · Physiological Reviews · doi:10.1152/physrev.00049.2010 · Cited by 1,140
Advances in Chemical Protein Modification
Boutureira, O., & Bernardes, G. J. L. (2015) · Chemical Reviews · doi:10.1021/cr500399p · Cited by 1,132
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,100
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Staphylococcus aureus Sortase, an Enzyme that Anchors Surface Proteins to the Cell Wall
Mazmanian, S. K., Liu, G., Ton-That, H., & Schneewind, O. (1999) · Science · doi:10.1126/science.285.5428.760 · Cited by 1,053
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Matching chelators to radiometals for radiopharmaceuticals
Price, E. W., & Orvig, C. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60304k · Cited by 1,018
Tumour acidosis: from the passenger to the driver's seat
Corbet, C., & Feron, O. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.77 · Cited by 988
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
PET versus SPECT: strengths, limitations and challenges
Rahmim, A., & Zaidi, H. (2008) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3282f3a515 · Cited by 834
Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 825
Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A., Schröder, C. P., Lub-de Hooge, M. N., & de Vries, E. G. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 805
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Cancer stem cells: The challenges ahead
Medema, J. P. (2013) · Nature Cell Biology · doi:10.1038/ncb2717 · Cited by 741
Giesel, F. L., Kratochwil, C., Lindner, T., Marschalek, M. M., Loktev, A., Lehnert, W., Debus, J., Jäger, D., Flechsig, P., Altmann, A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215913 · Cited by 740
Bensch, F., van der Veen, E. L., Lub-de Hooge, M. N., Jorritsma-Smit, A., Boellaard, R., Kok, I. C., Oosting, S. F., Schröder, C. P., Hiltermann, T. J. N., van der Wekken, A. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0255-8 · Cited by 732
First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*
Badawi, R. D., Shi, H., Hu, P., Chen, S., Xu, T., Price, P. M., Ding, Y., Spencer, B. A., Nardo, L., Liu, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.226498 · Cited by 722
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 716
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T. A., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00050-9 · Cited by 614
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 611
Saunders, L. R., Bankovich, A. J., Anderson, W. C., Aujay, M. A., Bheddah, S., Black, K., Desai, R., Escarpe, P. A., Hampl, J., Laysang, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9459 · Cited by 600
Tap, W. D., Jones, R. L., Van Tine, B. A., Chmielowski, B., Elias, A. D., Adkins, D., Agulnik, M., Cooney, M. M., Livingston, M. B., Pennock, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30587-6 · Cited by 584
Rudin, C. M., Pietanza, M. C., Bauer, T. M., Ready, N., Morgensztern, D., Glisson, B. S., Byers, L. A., Johnson, M. L., Burris, H. A., Robert, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30565-4 · Cited by 574
Strategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S., & Conrath, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806889200 · Cited by 572
Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Orlova, A., Magnusson, M., Eriksson, T. L. J., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3521 · Cited by 568
A general strategy for the evolution of bond-forming enzymes using yeast display
Chen, I., Dorr, B. M., & Liu, D. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101046108 · Cited by 565
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Loktev, A., Lindner, T., Burger, E.-M., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Marmé, F., Jäger, D., Mier, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224469 · Cited by 554
Beauchemin, N., & Arabzadeh, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9444-6 · Cited by 538
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Efficient production of high specific activity 64Cu using a biomedical cyclotron
McCarthy, D. W., Shefer, R. E., Klinkowstein, R. E., Bass, L. A., Margeneau, W. H., Cutler, C. S., Anderson, C. J., & Welch, M. J. (1997) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(96)00157-6 · Cited by 533
Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A. K., Navarro, V., Knudsen, B., & Bander, N. H. (1997) · PubMed · Cited by 528
Bioconjugation with Maleimides: A Useful Tool for Chemical Biology
Ravasco, J. M. J. M., Faustino, H., Trindade, A., & Gois, P. M. P. (2019) · Chemistry – A European Journal · doi:10.1002/chem.201803174 · Cited by 520
Young, C. L., Britton, Z. T., & Robinson, A. S. (2012) · Biotechnology Journal · doi:10.1002/biot.201100155 · Cited by 505
Beyond the margins: real-time detection of cancer using targeted fluorophores
Zhang, R. R., Schroeder, A. B., Grudzinski, J. J., Rosenthal, E. L., Warram, J. M., Pinchuk, A. N., Eliceiri, K. W., Kuo, J. S., & Weichert, J. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.212 · Cited by 485
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
Niemeijer, A. N., Leung, D., Huisman, M. C., Bahce, I., Hoekstra, O. S., van Dongen, G. A. M. S., Boellaard, R., Du, S., Hayes, W., Smith, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07131-y · Cited by 484
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Near-Infrared Photoimmunotherapy of Cancer
Kobayashi, H., & Choyke, P. L. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00273 · Cited by 479
The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
Lemmon, M. A., Schlessinger, J., & Ferguson, K. M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020768 · Cited by 475
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 471
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P. C., Kolstad, A., d’Amore, F., Diaz, M. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2015 · Cited by 460
Constitutive and antibody-induced internalization of prostate-specific membrane antigen.
Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., Rahmati, R., & Bander, N. H. (1998) · PubMed · Cited by 458
Kaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and synthesis
Nguyen, G. K. T., Wang, S., Qiu, Y., Hemu, X., Lian, Y., & Tam, J. P. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1586 · Cited by 431
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F. P., Gevaert, T., Simon, P., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162024 · Cited by 429
Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2020) · mAbs · doi:10.1080/19420862.2019.1703531 · Cited by 429
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Tagawa, S. T., Milowsky, M. I., Morris, M., Vallabhajosula, S., Christos, P., Akhtar, N. H., Osborne, J., Goldsmith, S. J., Larson, S., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427
A Novel Method of 18F Radiolabeling for PET
McBride, W. J., Sharkey, R. M., Karacay, H., D'Souza, C. A., Rossi, E. A., Laverman, P., Chang, C.-H., Boerman, O. C., & Goldenberg, D. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060418 · Cited by 418
89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
Holland, J. P., Divilov, V., Bander, N. H., Smith-Jones, P. M., Larson, S. M., & Lewis, J. S. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076174 · Cited by 418
Ladenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., Brock, P., Michon, J. M., Owens, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30578-3 · Cited by 418
Standardized methods for the production of high specific-activity zirconium-89
Holland, J. P., Sheh, Y., & Lewis, J. S. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.05.007 · Cited by 408
Kotagiri, N., Sudlow, G. P., Akers, W. J., & Achilefu, S. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2015.17 · Cited by 404
Clarke-Pearson, D. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0901926 · Cited by 400
Investigations of avidin and biotin for imaging applications.
Hnatowich, D. J., Virzi, F., & Rusckowski, M. (1987) · PubMed · Cited by 398
Radiometals for Combined Imaging and Therapy
Cutler, C. S., Hennkens, H. M., Sisay, N., Huclier-Markai, S., & Jurisson, S. S. (2013) · Chemical Reviews · doi:10.1021/cr3003104 · Cited by 395
Divgi, C. R., Pandit-Taskar, N., Jungbluth, A. A., Reuter, V. E., Gönen, M., Ruan, S., Pierre, C., Nagel, A., Pryma, D. A., Humm, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70044-x · Cited by 387
Affibody Molecules in Biotechnological and Medical Applications
Ståhl, S., Gräslund, T., Eriksson Karlström, A., Frejd, F. Y., Nygren, P.-Å., & Löfblom, J. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.04.007 · Cited by 382
Molecular tracers for the PET and SPECT imaging of disease
Pimlott, S. L., & Sutherland, A. (2011) · Chem. Soc. Rev. · doi:10.1039/b922628c · Cited by 379
Insulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation
Kemper, K., Sprick, M. R., de Bree, M., Scopelliti, A., Vermeulen, L., Hoek, M., Zeilstra, J., Pals, S. T., Mehmet, H., Stassi, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1820 · Cited by 372
Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365
Gebhart, G., Lamberts, L. E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv577 · Cited by 355
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., & Chatal, J.-F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8471 · Cited by 351
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Meric-Bernstam, F., Johnson, A. M., Dumbrava, E. E. I., Raghav, K., Balaji, K., Bhatt, M., Murthy, R. K., Rodon, J., & Piha-Paul, S. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2275 · Cited by 349
Catenacci, D. V. T., Tebbutt, N. C., Davidenko, I., Murad, A. M., Al-Batran, S.-E., Ilson, D. H., Tjulandin, S., Gotovkin, E., Karaszewska, B., Bondarenko, I., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30566-1 · Cited by 348
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Maute, R. L., Gordon, S. R., Mayer, A. T., McCracken, M. N., Natarajan, A., Ring, N. G., Kimura, R., Tsai, J. M., Manglik, A., Kruse, A. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519623112 · Cited by 347
Site‐Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
Jeger, S., Zimmermann, K., Blanc, A., Grünberg, J., Honer, M., Hunziker, P., Struthers, H., & Schibli, R. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201004243 · Cited by 344
Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Photo-Triggered Click Chemistry for Biological Applications
Herner, A., & Lin, Q. (2016) · Topics in Current Chemistry · doi:10.1007/s41061-015-0002-2 · Cited by 339
Vegt, E., de Jong, M., Wetzels, J. F. M., Masereeuw, R., Melis, M., Oyen, W. J. G., Gotthardt, M., & Boerman, O. C. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.075101 · Cited by 334
Spigel, D. R., Edelman, M. J., O’Byrne, K., Paz-Ares, L., Mocci, S., Phan, S., Shames, D. S., Smith, D., Yu, W., Paton, V. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2160 · Cited by 333
A definition of molecular imaging.
Mankoff, D. A. (2007) · PubMed · Cited by 332
Hu, S., Shively, L., Raubitschek, A. A., Sherman, M. A., Williams, L. E., Wong, J. Y., Shively, J. E., & Wu, A. M. (1996) · PubMed · Cited by 330
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan, R., Thomas, A., Alewine, C., Le, D. T., Jaffee, E. M., & Pastan, I. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.3672 · Cited by 325
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response
Larimer, B. M., Wehrenberg-Klee, E., Dubois, F., Mehta, A., Kalomeris, T., Flaherty, K., Boland, G., & Mahmood, U. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3346 · Cited by 325
[25] Yeast surface display for directed evolution of protein expression, affinity, and stability
Boder, E. T., & Wittrup, K. D. (2000) · Methods in Enzymology · doi:10.1016/s0076-6879(00)28410-3 · Cited by 324
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
Contardi, E., Palmisano, G. L., Tazzari, P. L., Martelli, A. M., Falà, F., Fabbi, M., Kato, T., Lucarelli, E., Donati, D., Polito, L., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21155 · Cited by 324
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy
Tavaré, R., Escuin-Ordinas, H., Mok, S., McCracken, M. N., Zettlitz, K. A., Salazar, F. B., Witte, O. N., Ribas, A., & Wu, A. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1707 · Cited by 320
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
Keu, K. V., Witney, T. H., Yaghoubi, S., Rosenberg, J., Kurien, A., Magnusson, R., Williams, J., Habte, F., Wagner, J. R., Forman, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2196 · Cited by 319
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J., & Ward, E. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2021 · Cited by 314
Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S. J., & Bander, N. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.154 · Cited by 313
HaloTag Technology: A Versatile Platform for Biomedical Applications
England, C. G., Luo, H., & Cai, W. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00191 · Cited by 311
Self-citationPerik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T. A., de Korte, M. A., Jonkman, S., Kosterink, J. G. W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8448 · Cited by 310
Baum, R. P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073239 · Cited by 308
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Radioactive Transition Metals for Imaging and Therapy
Boros, E., & Packard, A. B. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00281 · Cited by 299
Sheikhbahaei, S., Afshar-Oromieh, A., Eiber, M., Solnes, L. B., Javadi, M. S., Ross, A. E., Pienta, K. J., Allaf, M. E., Haberkorn, U., Pomper, M. G., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3780-7 · Cited by 295
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., Honda, N., Kodaira, M., Yamamoto, H., Yunokawa, M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.118612 · Cited by 294
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Rossin, R., van den Bosch, S. M., ten Hoeve, W., Carvelli, M., Versteegen, R. M., Lub, J., & Robillard, M. S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400153y · Cited by 291
Humanized Mice for the Study of Immuno-Oncology
De La Rochere, P., Guil-Luna, S., Decaudin, D., Azar, G., Sidhu, S. S., & Piaggio, E. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.07.001 · Cited by 291
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
Zhang, T., Song, X., Xu, L., Ma, J., Zhang, Y., Gong, W., Zhang, Y., Zhou, X., Wang, Z., Wang, Y., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2160-x · Cited by 290
Genetics and Pathogenesis of Inflammatory Bowel Disease
Liu, T.-C., & Stappenbeck, T. S. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044152 · Cited by 289
Nanobody: The “Magic Bullet” for Molecular Imaging?
Chakravarty, R., Goel, S., & Cai, W. (2014) · Theranostics · doi:10.7150/thno.8006 · Cited by 288
Self-citationTherapy resistance mediated by cancer stem cells
Steinbichler, T. B., Dudás, J., Skvortsov, S., Ganswindt, U., Riechelmann, H., & Skvortsova, I.-I. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.11.006 · Cited by 286
Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1277306 · Cited by 281
CD146, a multi-functional molecule beyond adhesion
Wang, Z., & Yan, X. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.11.049 · Cited by 281
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
Behr, T. M., Goldenberg, D. M., & Becker, W. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050216 · Cited by 274
Dynamic whole-body PET imaging: principles, potentials and applications
Rahmim, A., Lodge, M. A., Karakatsanis, N. A., Panin, V. Y., Zhou, Y., McMillan, A., Cho, S., Zaidi, H., Casey, M. E., & Wahl, R. L. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4153-6 · Cited by 273
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
Langbein, T., Weber, W. A., & Eiber, M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220566 · Cited by 269
Souweidane, M. M., Kramer, K., Pandit-Taskar, N., Zhou, Z., Haque, S., Zanzonico, P., Carrasquillo, J. A., Lyashchenko, S. K., Thakur, S. B., Donzelli, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30322-x · Cited by 267
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Sörensen, J., Velikyan, I., Sandberg, D., Wennborg, A., Feldwisch, J., Tolmachev, V., Orlova, A., Sandström, M., Lubberink, M., Olofsson, H., et al. (2016) · Theranostics · doi:10.7150/thno.13502 · Cited by 264
Aide, N., Hicks, R. J., Le Tourneau, C., Lheureux, S., Fanti, S., & Lopci, E. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4171-4 · Cited by 263
Nanobodies: Chemical Functionalization Strategies and Intracellular Applications
Schumacher, D., Helma, J., Schneider, A. F. L., Leonhardt, H., & Hackenberger, C. P. R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708459 · Cited by 260
Sörensen, J., Sandberg, D., Sandström, M., Wennborg, A., Feldwisch, J., Tolmachev, V., Åström, G., Lubberink, M., Garske-Román, U., Carlsson, J., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131243 · Cited by 258
The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
Afshar-Oromieh, A., Babich, J. W., Kratochwil, C., Giesel, F. L., Eisenhut, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170720 · Cited by 257
Pandit-Taskar, N., Postow, M. A., Hellmann, M. D., Harding, J. J., Barker, C. A., O’Donoghue, J. A., Ziolkowska, M., Ruan, S., Lyashchenko, S. K., Tsai, F., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229781 · Cited by 257
Exploiting Nanobodies’ Singular Traits
Ingram, J. R., Schmidt, F. I., & Ploegh, H. L. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053327 · Cited by 254
IFN-γ: A cytokine at the right time, is in the right place
Burke, J. D., & Young, H. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.05.002 · Cited by 254
Supuran, C. T., Alterio, V., Di Fiore, A., D’ Ambrosio, K., Carta, F., Monti, S. M., & De Simone, G. (2018) · Medicinal Research Reviews · doi:10.1002/med.21497 · Cited by 253
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Pastan, I., & Hassan, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0337 · Cited by 252
Isotype and glycoform selection for antibody therapeutics
Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252
Use of rituximab, the new FDA-approved antibody
Leget, G. A., & Czuczman, M. S. (1998) · Current Opinion in Oncology · doi:10.1097/00001622-199811000-00012 · Cited by 251
Total-body imaging: Transforming the role of positron emission tomography
Cherry, S. R., Badawi, R. D., Karp, J. S., Moses, W. W., Price, P., & Jones, T. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6169 · Cited by 251
Cho, S. Y., Lipson, E. J., Im, H.-J., Rowe, S. P., Gonzalez, E. M., Blackford, A., Chirindel, A., Pardoll, D. M., Topalian, S. L., & Wahl, R. L. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188839 · Cited by 251
Click Chemistry and Radiochemistry: The First 10 Years
Meyer, J.-P., Adumeau, P., Lewis, J. S., & Zeglis, B. M. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00561 · Cited by 248
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
Kramer, K., Kushner, B. H., Modak, S., Pandit-Taskar, N., Smith-Jones, P., Zanzonico, P., Humm, J. L., Xu, H., Wolden, S. L., Souweidane, M. M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0038-7 · Cited by 247
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
Rashidian, M., Ingram, J. R., Dougan, M., Dongre, A., Whang, K. A., LeGall, C., Cragnolini, J. J., Bierie, B., Gostissa, M., Gorman, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161950 · Cited by 246
The regulatory crosstalk between kinases and proteases in cancer
López-Otín, C., & Hunter, T. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2823 · Cited by 244
Adnectins: engineered target-binding protein therapeutics
Lipovsek, D. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq097 · Cited by 242
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180870 · Cited by 242
Cai, W., Chen, K., He, L., Cao, Q., Koong, A., & Chen, X. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0361-6 · Cited by 241
Self-citationMerchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., Huang, A., Yang, N.-Y., Nishimura, M., Greve, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302725110 · Cited by 236
Lim, R. K. V., & Lin, Q. (2011) · Accounts of Chemical Research · doi:10.1021/ar200021p · Cited by 235
Chatal, J.-F., Campion, L., Kraeber-Bodéré, F., Bardet, S., Vuillez, J.-P., Charbonnel, B., Rohmer, V., Chang, C.-H., Sharkey, R. M., Goldenberg, D. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4917 · Cited by 232
Pretargeted Imaging and Therapy
Altai, M., Membreno, R., Cook, B. E., Максимилианович, Т. В., & Zeglis, B. M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.189944 · Cited by 231
Xavier, C., Vaneycken, I., D’huyvetter, M., Heemskerk, J., Keyaerts, M., Vincke, C., Devoogdt, N., Muyldermans, S., Lahoutte, T., & Caveliers, V. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111021 · Cited by 230
Signaling by Antibodies: Recent Progress
Bournazos, S., Wang, T. T., Dahan, R., Maamary, J., & Ravetch, J. V. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052433 · Cited by 229
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
D'Huyvetter, M., Vincke, C., Xavier, C., Aerts, A., Impens, N., Baatout, S., De Raeve, H., Muyldermans, S., Caveliers, V., Devoogdt, N., et al. (2014) · Theranostics · doi:10.7150/thno.8156 · Cited by 225
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
on behalf of the MErCuRIC consortium, Bradley, C. A., Salto-Tellez, M., Laurent-Puig, P., Bardelli, A., Rolfo, C., Tabernero, J., Khawaja, H. A., Lawler, M., Johnston, P. G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.40 · Cited by 225
Welt, S., Scott, A. M., Divgi, C. R., Kemeny, N. E., Finn, R. D., Daghighian, F., Germain, J. S., Richards, E. C., Larson, S. M., & Old, L. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1787 · Cited by 223
Bispecific antibodies for cancer therapy: A review
Krishnamurthy, A., & Jimeno, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.002 · Cited by 223
Scott, A. M., Lee, F.-T., Tebbutt, N., Herbertson, R., Gill, S. S., Liu, Z., Skrinos, E., Murone, C., Saunder, T. H., Chappell, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611693104 · Cited by 222
Sundaresan, G., Yazaki, P. J., Shively, J. E., Finn, R. D., Larson, S. M., Raubitschek, A. A., Williams, L. E., Chatziioannou, A. F., Gambhir, S. S., & Wu, A. M. (2003) · PubMed · Cited by 222
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
Lütje, S., Heskamp, S., Cornelissen, A. S., Poeppel, T. D., Broek, S. A. M. W. V. D., Rosenbaum-Krumme, S., Bockisch, A., Gotthardt, M., Rijpkema, M., & Boerman, O. C. (2015) · Theranostics · doi:10.7150/thno.13348 · Cited by 222
In vivo imaging with antibodies and engineered fragments
Freise, A. C., & Wu, A. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.001 · Cited by 220
Noninvasive imaging of immune responses
Rashidian, M., Keliher, E. J., Bilate, A. M., Duarte, J. N., Wojtkiewicz, G. R., Jacobsen, J. T., Cragnolini, J., Swee, L. K., Victora, G. D., Weissleder, R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502609112 · Cited by 218
Cooper, M. S., Ma, M. T., Sunassee, K., Shaw, K. P., Williams, J. D., Paul, R. L., Donnelly, P. S., & Blower, P. J. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300037w · Cited by 217
Zeng, Q., Li, W., Lu, D., Wu, Z., Duan, H., Luo, Y., Feng, J., Yang, D., Fu, L., & Yan, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111053108 · Cited by 217
Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Sheehan, C. E., Vallabhajosula, S., Goldsmith, S. J., Ross, J. S., & Bander, N. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8097 · Cited by 217
Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans
Ward, E. S. (2003) · International Immunology · doi:10.1093/intimm/dxg018 · Cited by 216
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Puca, L., Gavyert, K., Sailer, V., Conteduca, V., Dardenne, E., Sigouros, M., Isse, K., Kearney, M., Vosoughi, A., Fernandez, L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0891 · Cited by 214
Camelid and shark single domain antibodies: Structural features and therapeutic potential
Könning, D., Zielonka, S., Grzeschik, J., Empting, M., Valldorf, B., Krah, S., Schröter, C., Sellmann, C., Hock, B., & Kolmar, H. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.10.019 · Cited by 214
A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth
Yan, X. (2003) · Blood · doi:10.1182/blood-2002-04-1004 · Cited by 214
Wu, A. M., Yazaki, P. J., Tsai, S.-W., Nguyen, K., Anderson, A.-L., McCarthy, D. W., Welch, M. J., Shively, J. E., Williams, L. E., Raubitschek, A. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150228297 · Cited by 214
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M., & Chang, C.-H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600982103 · Cited by 209
CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis
Jiang, T., Zhuang, J., Duan, H., Luo, Y., Zeng, Q., Fan, K., Yan, H., Lu, D., Ye, Z., Hao, J., et al. (2012) · Blood · doi:10.1182/blood-2012-01-406108 · Cited by 209
Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
Knowles, S. M., & Wu, A. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4887 · Cited by 209
Utilizing the power of Cerenkov light with nanotechnology
Shaffer, T. M., Pratt, E. C., & Grimm, J. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2016.301 · Cited by 208
Wong, E. H., Weisman, G. R., Hill, D. C., Reed, D. P., Rogers, M. E., Condon, J. S., Fagan, M. A., Calabrese, J. C., Lam, K., Guzei, I. A., et al. (2000) · Journal of the American Chemical Society · doi:10.1021/ja001295j · Cited by 207
Kenanova, V., Olafsen, T., Crow, D. M., Sundaresan, G., Subbarayan, M., Carter, N. H., Ikle, D. N., Yazaki, P. J., Chatziioannou, A. F., Gambhir, S. S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.622.65.2 · Cited by 206
Graff, C. P., & Wittrup, K. D. (2003) · PubMed · Cited by 205
Targeting of activated fibroblasts for imaging and therapy
Lindner, T., Loktev, A., Giesel, F., Kratochwil, C., Altmann, A., & Haberkorn, U. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0069-0 · Cited by 205
A tale of two antibodies: obinutuzumab versus rituximab
Freeman, C. L., & Sehn, L. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15232 · Cited by 201
Molecular Pathways: HER3 Targeted Therapy
Gala, K., & Chandarlapaty, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1549 · Cited by 199
PennPET Explorer: Design and Preliminary Performance of a Whole-Body Imager
Karp, J. S., Viswanath, V., Geagan, M. J., Muehllehner, G., Pantel, A. R., Parma, M. J., Perkins, A. E., Schmall, J. P., Werner, M. E., & Daube-Witherspoon, M. E. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229997 · Cited by 198
Anwar, H., Sachpekidis, C., Winkler, J., Kopp-Schneider, A., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou-Strauss, A. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3870-6 · Cited by 197
Pandit-Taskar, N., O'Donoghue, J. A., Durack, J. C., Lyashchenko, S. K., Cheal, S. M., Beylergil, V., Lefkowitz, R. A., Carrasquillo, J. A., Martinez, D. F., Fung, A. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0552 · Cited by 195
Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET
Aerts, H. J. W. L., Dubois, L., Perk, L., Vermaelen, P., van Dongen, G. A. M. S., Wouters, B. G., & Lambin, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054312 · Cited by 194
Oliveira, S., van Dongen, G. A. M. S., Walsum, M. S.-V., Roovers, R. C., Stam, J. C., Mali, W., van Diest, P. J., & van Bergen en Henegouwen, P. M. P. (2012) · Molecular Imaging · doi:10.2310/7290.2011.00025 · Cited by 194
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
Hettich, M., Braun, F., Bartholomä, M. D., Schirmbeck, R., & Niedermann, G. (2016) · Theranostics · doi:10.7150/thno.15253 · Cited by 194
Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandström, M., Nilsson, F. Y., Wennborg, A., Abrahmsén, L., & Feldwisch, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2887 · Cited by 193
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab
England, C. G., Ehlerding, E. B., Hernandez, R., Rekoske, B. T., Graves, S. A., Sun, H., Liu, G., McNeel, D. G., Barnhart, T. E., & Cai, W. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177857 · Cited by 193
Self-citation
Cited by
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Guo, X., Li, Y., Zhang, M., Cao, K., Tian, Y., Qi, Y., Li, S., Li, K., Yu, X., & Ma, L. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202010829 · Cited by 345
Radiochemistry for positron emission tomography
Rong, J., Haider, A., Jeppesen, T. E., Josephson, L., & Liang, S. H. (2023) · Nature Communications · doi:10.1038/s41467-023-36377-4 · Cited by 294
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
“A variety of radionuclides and monoclonal antibodies have been used to develop immunoPET probes, which has been driven by advances in radiochemistry and conjugation strategies 152 .”
Background
Metadata
- Authors
- Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-23
- Volume
- 120
- Issue
- 8
- Pages
- 3787-3851
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W3012903956
- Cited by
- 484
- References
- 717
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.